SGO速递丨PARPi耐受性和剂量调整的比较( 二 )


[1]Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med. 2019;381(25):2416-2428.
[2]Moore K, Colombo N, Scambia G, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018;379(26):2495-2505.
[3]González-Martín A, Pothuri B, Vergote I, et al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019 Dec 19;381(25):2391-2402.
[4]William Bradley, Kathleen Moore, Nicoletta Colombo, et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: 5-year follow-up from SOLO1. SGO 2021.
[5]Melissa M. Hardesty, Thomas Krivak, Gail S. Wright, et al. Phase 2 OVARIO Study of Niraparib + Bevacizumab Therapy in Advanced Ovarian Cancer Following Frontline Platinum-Based Chemotherapy with Bevacizumab. SGO 2021, Poster #22.
[6]Rebecca Arend, David M O'Malley, Susana Banerjee, et al. Comparative tolerability and dose modifications of poly(ADP-ribose) polymerase inhibitors in ovarian cancer: a retrospective cohort study of US healthcare claims data. SGO 2021, Poster 10487.

推荐阅读